Company intelligence / Profile preview

Trellis Bioscience

Redwood City, California, United States

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Lead product TRL1068 has received FDA Fast Track, QIDP, and Orphan Drug designations. It has demonstrated clinical proof of concept in reducing biofilm burden in prosthetic joint infections.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

6 assets

calpurbatug

5 more assets in the full pipeline.

Request access →

Partnerships

Relevant Biosciences (oncology)

Beyond the preview

Go deeper on Trellis Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trellis Bioscience.

Explore the full profile